Global Antibody-oligonucleotide Conjugates (AOCs) Market Insights, Forecast to 2031

The global Antibody-oligonucleotide Conjugates (AOCs) market is projected to grow from US$ 3.12 million in 2026 to US$ 291.41 million by 2031, at a Compound Annual Growth Rate (CAGR) of 147.78% during the forecast period (2026-2031).

The US & Canada market for Antibody-oligonucleotide Conjugates (AOCs) is estimated to increase from $ 2.04 million in 2026 to reach $ 165.03 million by 2031, at a CAGR of 140.81% during the forecast period of 2026 through 2031.

The Europe market for Antibody-oligonucleotide Conjugates (AOCs) is estimated to increase from $ 1.08 million in 2026 to reach $ 96.95 million by 2031, at a CAGR of 145.73% during the forecast period of 2026 through 2031.

The global key companies of Antibody-oligonucleotide Conjugates (AOCs) include Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, Gennao Bio, ChainGen Bio and Denali Therapeutics, etc. As innovations continue to emerge in the field of AOCs, competition is also gradually intensifying. Major companies continue to launch new drug candidates, especially in the fields of cancer and neurodegenerative diseases, and the competition for market share will become more intense.

Report Includes

This report presents an overview of global market for Antibody-oligonucleotide Conjugates (AOCs) market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2024, and projections of CAGR through 2031.

This report researches the key producers of Antibody-oligonucleotide Conjugates (AOCs), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Antibody-oligonucleotide Conjugates (AOCs), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antibody-oligonucleotide Conjugates (AOCs) revenue, market share and industry ranking of main companies, data from 2020 to 2024. Identification of the major stakeholders in the global Antibody-oligonucleotide Conjugates (AOCs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Antibody-oligonucleotide Conjugates (AOCs) revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, Gennao Bio, ChainGen Bio and Denali Therapeutics, etc.

Market Segmentation

By Company

Avidity Biosciences

Dyne Therapeutics

Tallac Therapeutics

Denali Therapeutics

Gennao Bio

ChainGen Bio

Segment by Type

Site-specific Conjugation

Random Conjugation

Segment by Application

Rare and Genetic Diseases

Cancer Treatment

Central Nervous System Disorders

By Region

North America

United States

Canada

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Europe

Germany

France

U.K.

Italy

Russia

Rest of Europe

Latin America

Mexico

Brazil

Middle East & Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Antibody-oligonucleotide Conjugates (AOCs) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antibody-oligonucleotide Conjugates (AOCs) companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: China by Type, and by Application, revenue for each segment.

Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody-oligonucleotide Conjugates (AOCs) revenue, gross margin, and recent development, etc.

Chapter 12: Analysis of industrial chain, sales channel, key raw materials and customers.

Chapter 13: Analyst's Viewpoints/Conclusions